PMID- 23336845
OWN - NLM
STAT- MEDLINE
DCOM- 20131021
LR  - 20151119
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Mar
TI  - Does pen help? A real-world outcomes study of switching from vial to disposable 
      pen among insulin glargine-treated patients with type 2 diabetes mellitus.
PG  - 230-6
LID - 10.1089/dia.2012.0253 [doi]
AB  - OBJECTIVE: The study was designed to evaluate real-world data on clinical and 
      economic outcome differences between patients with type 2 diabetes mellitus 
      (T2DM) who use insulin glargine with vial-and-syringe delivery and those who 
      switch to pen administration. SUBJECTS AND METHODS: This retrospective study 
      analyzed medical and pharmacy claims information from the national managed-care 
      IMPACT((R)) database (Ingenix Inc., Salt Lake City, UT). Adults with T2DM treated 
      with insulin glargine were evaluated. Clinical and economic outcomes over 1 year 
      were compared between individuals who had converted from administering glargine 
      via vial-and-syringe to the SoloSTAR((R)) (sanofi-aventis U.S., Bridgewater, NJ) 
      pen (Switchers) and patients who continued to use vial-and-syringe administration 
      (Continuers). Patients from each cohort were matched using propensity score 
      matching for a comparison sample. RESULTS: In total, 3,893 eligible patients were 
      identified (665 Switchers and 3,228 Continuers), with a matched cohort with 603 
      patients in each group. Baseline characteristics were similar between groups. 
      One-year treatment persistence was significantly higher with Switchers versus 
      Continuers (65.3% vs. 49.8%; P<0.0001). Medication possession ratio was also 
      significantly higher among Switchers (0.79 vs. 0.76; P=0.0173). Insulin use and 
      glycemic control were similar between groups. Healthcare utilization and total 
      costs were also similar between groups. Higher prescription costs among Switchers 
      were offset by lower overall and diabetes-related outpatient and inpatient costs. 
      CONCLUSIONS: Switching from insulin glargine vial-and-syringe administration to 
      pen delivery resulted in improved treatment adherence and persistence, with 
      comparable clinical and economic outcomes.
FAU - Xie, Lin
AU  - Xie L
AD  - STATinMED Research, Inc., Ann Arbor, MI, USA.
FAU - Zhou, Steve
AU  - Zhou S
FAU - Wei, Wenhui
AU  - Wei W
FAU - Gill, Jasvinder
AU  - Gill J
FAU - Pan, Chunshen
AU  - Pan C
FAU - Baser, Onur
AU  - Baser O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130121
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Anxiety
MH  - Diabetes Mellitus, Type 2/*drug therapy/psychology
MH  - Disposable Equipment
MH  - *Drug Delivery Systems/psychology
MH  - Drug Dosage Calculations
MH  - Equipment Design
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Injections, Subcutaneous/adverse effects/psychology
MH  - Insulin Glargine
MH  - Insulin, Long-Acting/*administration & dosage
MH  - Male
MH  - Medication Adherence/statistics & numerical data
MH  - Middle Aged
MH  - Pain/etiology/psychology
MH  - Patient Preference/statistics & numerical data
MH  - Patient Satisfaction/statistics & numerical data
MH  - Retrospective Studies
MH  - Syringes/adverse effects
EDAT- 2013/01/23 06:00
MHDA- 2013/10/22 06:00
CRDT- 2013/01/23 06:00
PHST- 2013/01/23 06:00 [entrez]
PHST- 2013/01/23 06:00 [pubmed]
PHST- 2013/10/22 06:00 [medline]
AID - 10.1089/dia.2012.0253 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Mar;15(3):230-6. doi: 10.1089/dia.2012.0253. Epub 
      2013 Jan 21.